Navigation Links
Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
Date:11/17/2009

ROCKVILLE, Md., Nov. 17 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) today provided a financial and business update for the third quarter ended September 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

For the third quarter of 2009, the Company reported a net loss of $5,096,983, or $0.15 per share, compared with a net loss of $3,177,957 or $0.10 per share, for the comparable 2008 period. The increase was due to a non-cash charge related to a change in accounting for certain warrants, offset in part by reductions in other expense categories. Net loss attributable to common stockholders for the first nine months of 2009 was $7,380,751 or $0.22 per share, compared with $8,410,081, or $0.26 per share, for the comparable period in 2008, resulting from a year to date gain in accounting for warrants, partially offset by increases in non-cash stock-based compensation expense, R&D and legal fees.

Cash, cash equivalents and short-term marketable securities at September 30, 2009 totaled approximately $2.4 million, compared with approximately $4.9 million at December 31, 2008. As of September 30, 2009, the Company estimated that cash on hand would be sufficient to meet its operating needs into the first quarter of 2010, including estimated costs associated with the clinical trials for its ALS programs planned for commencement in the U.S. in 2010.

For the nine months ended September 30, 2009, cash used in operating activities totaled $3,613,084, a decrease of $1,118,358 or 24% compared to the same period in the prior year, primarily attributable to an increase of short term financing by vendors, employees and other service providers and a reduction in spending, particular
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
2. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
3. Cadus Reports Third Quarter 2009 Results
4. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
5. Sinovac Reports Unaudited Third Quarter 2009 Financial Results
6. Soligenix Reports Third Quarter 2009 Financial Results
7. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
8. Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
9. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
10. China Pharma Holdings, Inc. Reports Third Quarter 2009 Financial Results and Corporate Updates
11. YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015  Multiple new research ... affect several important health factors. From their impact on ... their positive effect on both gut health and vascular ... (EB) detail our latest understanding of walnuts, inner workings. ... Boston , this annual meeting attracts an international ...
(Date:3/30/2015)... , March 30, 2015 US-Australian drug ... and its subsidiary, CanTx, Inc., and Yale University, on ... Cantrixil. The data was presented as an oral presentation ... Yale Medical School to the 62 nd Annual ... San Francisco, CA. ...
(Date:3/30/2015)... , March 30, 2015  Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ...  Case No. 3:13-cv-03494-M and  Spherix v. Uniden , ... District Court for the Northern District of ... Spherix v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, ...
(Date:3/30/2015)... Richmond Pharmacology nimmt weltweit ... ist das erste Zentrum weltweit, das in Zusammenarbeit ... in London in einer ... an einem Patienten begonnen hat. Das Therapeutikum wurde ... (ATTR), einer seltenen Herz- und Nervenkrankheit. ...
Breaking Biology Technology:New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3
... Valkee ( http://valkee.com ), the inventor of the world,s ... of Oulu present two clinical trials at the 11th ... Budapest on November 9 th -11 th . In ... supplement of the International Journal of Psychiatry in Clinical ...
... 7, 2011 IDEXX Laboratories, Inc. (NASDAQ: ... acquired the research and diagnostic laboratory (RADIL) business ... University of Missouri for $43 million in cash. ... and diagnostic testing services to bioresearch customers. ...
... Halozyme Therapeutics, Inc. (NASDAQ: ... targeting the extracellular matrix for the diabetes, ... results for the third quarter of 2011 and discussed ... "The past few months highlight the progress ...
Cached Biology Technology:Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu 2Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu 3IDEXX Laboratories Acquires the RADIL Reference Laboratory from the University of Missouri 2IDEXX Laboratories Acquires the RADIL Reference Laboratory from the University of Missouri 3IDEXX Laboratories Acquires the RADIL Reference Laboratory from the University of Missouri 4Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 2Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 3Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 4Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 5Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 6Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 7
(Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... Latin America . Annual estimates and ...
(Date:3/17/2015)... 17, 2015 Emotient, the leader in ... announced general availability of Emotient Analytics , ... analysis of facial expressions. The system analyzes videos ... products and services. It delivers audience response metrics ... - as derived from facial evidence of emotional ...
(Date:3/12/2015)... March 12, 2015 The mascots of the ... Hospital, part of Wake Forest Baptist Medical Center. They ... the 2015 ACC Men,s Basketball Tournament. Young patients enjoyed ... and getting their autographs. Brenner Children,s Hospital ... is the only children,s hospital in northwest ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... no good evidence supporting a harmful effect of exercise on ... according to a review of studies published in this month,s ... is an extremely popular leisure-time activity in many countries throughout ... the modern lifestyle. It is widely promoted in as being ...
... SVOX, the leading provider of,embedded speech solutions ... Group of Siemens AG, according to SVOX CEO ... of Siemens AG developed,over 25 years, including the ... patent families. The majority of the Professional,Speech Processing ...
... Ill. -- Most people know that too much sodium from ... that people trying to lower their blood pressure should also ... to sodium. Researchers found that the ratio of sodium-to-potassium ... disease than sodium or potassium alone. "There isn,t ...
Cached Biology News:SVOX Acquires Speech Processing Unit of Siemens AG, Expands Into Speech Recognition and Speech Dialog 2Cutting salt isn't the only way to reduce blood pressure 2
... Compound(s) tested through 63 ... assays spanning a broad ... panel includes many non ... several non-selective assays. ...
...
... The Genome Sequencer 20 System revolutionizes ... massively parallel fashion. The Genome Sequencer ... accessories Reagents and consumables for library ... for mapping and de novo assembly ...
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Biology Products: